Matrix Pharmaceutical, Inc.
15Patents
0Active
15Granted
30Portfolio score
Filing activity: May 21, 1985 → Nov 15, 2000
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4619913A | Treatments employing drug-containing matrices for introduction into cellular lesion areas | Human Necessities | 123 | Expired |
| US5573781A | Methods and compositions for the treatment of a host with a cellular proliferative disease | Human Necessities | 54 | Expired |
| US4978332A | Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas | Human Necessities | 48 | Expired |
| US5597578A | TGF-.beta. protein compositions for inhibition of cell proliferation | Human Necessities | 41 | Expired |
| USRE33375E | Treatments employing drug-containing matrices for introduction into cellular lesion areas | General | 36 | Expired |
| USRE35748E | Treatments employing drug containing matrices for introduction into cellular lesion areas | General | 19 | Expired |
| US6544962B1 | Methods for treating cellular proliferative disorders | Human Necessities | 10 | Expired |
| US5980946A | Collagen formulations | Human Necessities | 10 | Expired |
| US6224883A | Process and composition for therapeutic cisplatin (CDDP) | Human Necessities | 9 | Expired |
| US5750146A | Translucent collagen formulations with a cytotoxic drug | Human Necessities | 9 | Expired |
| US6077545A | Process and composition for therapeutic cisplatin (CDDP) | Human Necessities | 9 | Expired |
| US5925246A | Apparatus for aseptic vortex flow concentration | Emerging Cross-Sectional Technologies | 8 | Expired |
| US5874402A | Use of cell membrane permeants in the treatment of cellular proliferative diseases | Human Necessities | 7 | Expired |
| US5874006A | Aseptic collagen concentration process | Performing Operations; Transporting | 3 | Expired |
| US5968355A | Apparatus for aseptic vortex flow concentration | Emerging Cross-Sectional Technologies | 2 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.